Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 3/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538625 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 | |
| SCHEMBL7152730 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 | |
| SCHEMBL22334084 | 0.78 | PI4KA (0.46) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 | |
| SCHEMBL10401684 | 0.78 | PI4KA (0.46) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 | |
| SCHEMBL22333913 | 0.78 | PI4KA (0.46) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 | |
| SCHEMBL7149845 | 0.78 | PI4KA (0.46) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 | |
| SCHEMBL7150205 | 0.76 | LMNA (0.63) | ALDH1A1SMN1; SMN2LMNAPOLBHSPA8 | |
| SCHEMBL7150210 | 0.76 | LMNA (0.63) | ALDH1A1SMN1; SMN2LMNAPOLBHSPA8 | |
| SCHEMBL27516530 | 0.76 | LMNA (0.63) | ALDH1A1SMN1; SMN2LMNAPOLBHSPA8 | |
| SCHEMBL7151907 | 0.74 | CDK5 (0.51) | ALDH1A1SMN1; SMN2LMNAPOLBCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642206-B2 | Useful in treating a wide variety of diseases including infections, infestations, neoplasms and autoimmune diseases | ICN PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6573248-B2 | Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| US-4021542-A | Derivatives of hydrazino-monosaccharides and aldohexoses which are useful as intermediates for preparing compounds or as compounds which lower the uric acid | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | ALDH1A1 592/4885SMN1; SMN2 724/4885LMNA 1677/4885 |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | ALDH1A1 592/4885SMN1; SMN2 724/4885LMNA 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.